Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the adequacy of supplies of the HRT drug Evorel Conti.

We are aware that supplies of Evorel Conti patches became unavailable at the end of November 2019 due to the divestment of the product to another company. The Evorel hormone replacement therapy (HRT) patch range has been divested to the company Theramex UK Limited.

The Department has been in contact with Theramex, who anticipates that supplies will become available from February 2020. We are working closely with this company to expedite the resupply date of the Evorel patch range including Evorel Conti.

We have been working closely with all suppliers of HRT preparations to maintain overall supply to patients. We have shared relevant information about the supply situation and availability of HRT products with the National Health Service on a regular basis. Patients affected are advised to discuss alternative treatment options with their clinician.